Peregrine Pharmaceuticals, Inc. (NASDAQ-PPHM) is a biopharmaceutical company developing and manufacturing innovative monoclonal antibodies for the treatment of cancer and serious viral infections.
A new national initiative involving where volunteers can be matched to a scientific research project, or clinical trial, for which they might qualify.
Interested adult volunteers, parents or caregivers register on the ResearchMatch Web site (www.researchmatch.org) and indicate their interest in participating in research studies. Both healthy volunteers and those with specific medical conditions can sign up.
Message 26090452
CRISP has a new site for checking on grants.
projectreporter.nih.gov
Government link for definions used in trials.
prsinfo.clinicaltrials.gov
Patent office definitions:
uspto.gov
Peregrine UTSW license agreement
faqs.org
Epstein Medibiotech settlement
On June 4, 2009, we signed a settlement agreement (the “June Settlement Agreement”) with CTL, Dr. Epstein, Clive Taylor, M.D. and Peisheng Hu, M.D. (collectively, the “CTL Parties”), providing for a settlement and release of all claims with respect to our previously disclosed litigation with those CTL Parties. Under the June Settlement Agreement, the parties dismissed all of their claims against each other in the lawsuit. In connection with the June Settlement Agreement, (1) we agreed to pay to CTL the sum of four hundred thousand dollars ($400,000) in eight equal monthly installments of fifty thousand dollars ($50,000) commencing upon execution of the June Settlement Agreement and continuing on the first business day of each succeeding month until paid in full, which amount is included in selling, general and administrative expenses in the accompanying consolidated financial statements during fiscal year 2009,
(2) CTL agreed to issue to us 950,000 shares of Medibiotech (which represents fifty percent (50%) of the shares of Medibiotech to be issued to and owned by CTL under the April Settlement Agreement), and
(3) we entered into a license agreement with Dr. Epstein effective as of September 20, 1995, pursuant to which Dr. Epstein granted us (i) a fully paid-up, royalty free, exclusive worldwide license to the murine clone TNT1 and (ii) a fully paid-up, royalty free, non-exclusive worldwide (except in the Peoples Republic of China) license to the murine clones TNT2 and TNT3. The foregoing license grants include our right to grant sublicenses, to make, have made, modify, have modified, use, sell and offer for sale, murine clone TNT1, TNT2 and TNT3 products and derivatives thereof, but not to sell the murine clones. We also granted back to Dr. Epstein a limited, fully paid-up, royalty free, exclusive license to the murine clone TNT1, with the right to grant sublicenses, to make, have made, modify, have modified, offer to sell, sell and use the murine clone TNT1 and its products solely in the Peoples Republic of China effective as of August 29, 2001. In consideration of the foregoing license grants, we paid Dr. Epstein the sum of one thousand dollars ($1,000), which amount was deducted from the initial $50,000 payment. In addition, the June Settlement Agreement contained full general releases between the Company and the CTL parties.
sec.gov |
